Clinical trial · Interventional
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
NCT00427583CI-TRIAL-00007750terminatedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): stopped due to slow recruitment and no effect
Summary
Brief summary (as posted)
This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Peripheral Nerve Sheath Tumors | Malignant Peripheral Nerve Sheath Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| imatinib mesylate | Drug | Imatinib Mesylate | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- STI571
- interventionNames
- Drug: imatinib mesylate
Primary outcomes (1)
- measure
- Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated.
- timeFrame
- Every 36 weeks
Secondary outcomes (3)
- measure
- Time to progression assessed by an MRI scan.
- timeFrame
- Every 36 weeks
- measure
- Overall survival
- timeFrame
- Every 36 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Patients ≥18 years of age * Histologically documented diagnosis of malignant MPNST * Unresectable local MPNST or metastatic MPNST and therefore incurable with any conventional multimodality approach Life expectancy of at least 6 months. Exclusion criteria: * Patient has received any other investigational agents within 28 days of first day of study drug dosing. * Chemotherapy and or radiotherapy in between the last 6 weeks before study entry, surgery in between the last 14 days before study entry. * Female patients who are pregnant or breast feeding or women of child bearing potential who are not using a highly effective method of birth control. * Known CNS metastases Other protocol-defined inclusion/exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.